Stockreport

SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)

SCYNEXIS, Inc.  (SCYX) 
Last scynexis, inc. earnings: 11/12 08:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.scynexis.com/investor-relations
PDF JERSEY CITY, N.J., Nov. 7, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often l [Read more]